Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.67 |
| ▸ | MAOA | P21397 | 16/20 | 0.67 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327001 | 0.89 | MAOB (0.84) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL1028361 | 0.82 | GSTP1 (0.57) | MAOBMAOAGSTP1NPC1ALDH1A1 | |
| SCHEMBL4095412 | 0.82 | MAOA (0.77) | MAOBMAOAGSTP1HSD17B1 | |
| SCHEMBL3994786 | 0.81 | HSD17B1 (0.59) | MAOBMAOAGSTP1HSD17B1NPC1 | |
| SCHEMBL1745161 | 0.81 | HSD17B1 (0.71) | HSD17B1NPC1ALDH1A1HPGDGRM5 | |
| SCHEMBL3451690 | 0.81 | MAOB (0.94) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL226640 | 0.81 | MAOB (1.00) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL30353268 | 0.80 | MAOB (0.84) | MAOBMAOAGSTP1NPC1ALDH1A1 | |
| SCHEMBL2524800 | 0.80 | MAOB (0.84) | MAOBMAOAGSTP1NPC1ALDH1A1 | |
| SCHEMBL23506817 | 0.77 | MAOB (0.74) | MAOBMAOANPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078420-B2 | Liquid crystal composition and liquid crystal display element | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIAL CO., LTD. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20190185751-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Shijiazhuang Chengzhi Yonghua Display Material Co., Ltd (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-1581509-B1 | 1-(AMINO)INDANES AS EDG RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| EP-1581509-A4 | 1-(AMINO)INDANES AND (1,2-DIHYDRO-3-AMINO)-BENZOFURANS, BENZOTHIOPHENES AND INDOLES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-7220734-B2 | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060161005-A1 | 1-(Amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists | MERCK SHARP & DOHME CORP. | 2006-07-20 | — | — | US | disclosed |
| EP-1581509-A2 | 1-(AMINO)INDANES AND (1,2-DIHYDRO-3-AMINO)-BENZOFURANS, BENZOTHIOPHENES AND INDOLES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058149-A2 | 1-(AMINO)INDANES AND (1,2-DIHYDRO-3-AMINO)-BENZOFURANS, BENZOTHIOPHENES AND INDOLES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | MAOB 494/4885MAOA 470/4885GSTP1 726/4885 |
| US-20060161005-A1 | 1-(Amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists | IDO1, IDO2, EDNRA | MAOB 1511/4885MAOA 1597/4885GSTP1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.